Immunological Strategies to Fight Skin Cancer

B. Berman, MD, PhD; O. A. Perez, MD; D. Zell, MD

Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami, Miami, USA

ABSTRACT

Skin cancer is the most common human cancer, and is currently considered a global epidemic. Recently, there has been a growing interest in immunomodulators, or upregulators of the immune response, for the treatment and cure of various forms of skin cancer, including melanoma and nonmelanoma skin cancers, cutaneous T-cell lymphoma, Kaposi’s sarcoma, cutaneous extramammary Paget’s disease, and vulvar intraepithelial carcinoma neoplasia. Strategies to augment the host’s immune response against cancer cells and/or cancer cell antigenicity have been investigated, including recombinant cytokines, immunomodulators, dendritic cell immunization, tumor antigen vaccination, T-cell-based immunotherapy, and gene therapy. Although the current standard of care for most of these cancers includes Mohs micrographic surgery, curettage, and cryo-, laser-, or radiotherapy, immunomodulators are becoming essential in the treatment of patients who are poor surgical candidates and/or require noninvasive therapy.

Key Words:
skin cancer, melanoma, squamous cell carcinoma, immunomodulators, interferon, imiquimod

Recently, there has been a growing interest in immunomodulators for the treatment and cure of skin cancers. The therapeutic effect of immunomodulators on melanoma and nonmelanoma skin cancers, cutaneous T-cell lymphoma (CTCL), Kaposi’s sarcoma (KS), cutaneous extramammary Paget’s disease, and vulvar intraepithelial carcinoma neoplasia (VIN) is currently being investigated. Today, immunomodulators are essential in the treatment of patients who are poor surgical candidates and/or require noninvasive therapy, and there is a growing interest in understanding the safety, mechanisms, and therapeutic effect of immunomodulators on skin cancers.

Interferon

Cutaneous Melanoma

In the United States, adjuvant high-dose interferon (IFN) therapy has become the standard of care for melanomas with a high risk of recurrence, and the FDA has approved the use of IFN-á-2b for the treatment of patients with melanomas thicker than 4mm and patients with lymph node metastasis. An early randomized prospective trial by Creagan, et al. did not find a significant difference between IFN-á-2b treated melanoma Stage I and II subjects vs. untreated controls. Although the experimental group had a longer disease-free survival (median, 17 months for the IFN-á-2b group vs. 10 months for the control group), the difference was notsignificant (p=0.09).¹ However, when Rusciani, et al. evaluated Stage II melanoma IFN-á-2b treated subjects vs. Stage II untreated controls, they found a metastasis rate of 19.6% (10 of 51 treated subjects) vs. 60% (18 of 30 untreated controls) at 3 years followup (p<0.0001), and a metastasis rate of 25% (4 of 16 treated subjects) vs. 63% (12 of 19 untreated controls) at 5 years follow-up (p<0.005). The Stage I melanoma IFN-á-2b treated subjects did not have a significantly different disease progression than the untreated Stage I controls at 3 and 5 years follow-up.²

IFN-á-2b therapy appears to be more effective in patients with lesions that have a poor prognosis. A recent study examined the combination of IFN-á-2b and surgery in high-risk melanoma patients. In this retrospective study of 150 patients, adjuvant high-dose IFN was an effective treatment option for patients with high-risk melanoma (Stage IIC, III) after definitive surgery. The 2-year and 5-year relapse-free survival rates were estimated at 48% and 36%, respectively.³

Basal Cell Carcinoma

The antiproliferative property of IFNs has also been employed in the treatment of patients with low-risk nodular basal cell carcinoma (nBCC) or superficial basal cell carcinoma (sBCC). Basal cell carcinoma (BCC) cells have been shown to express the CD95 ligand (FasL) and CD95 receptor (FasR), whereas the surrounding CD4+ T cells predominantly express FasR. Thus, in IFN treated patients, BCC may regress by FasR–FasL mediated apoptosis.⁴ Intralesional IFN-á-2b at a concentration of 1.5 million international units (IU) used over a 3 to 4-week period has been shown to have an overall success rate of up to 100%.^5,6 However, when used for aggressive forms of BCC, this protocol has resulted in a cure rate of only 27% of treated patients.⁷ Therefore, IFN treatment of BCC remains an alternative only for patients with low-risk nodular or superficial BCC.

Squamous Cell Carcinoma/ Actinic Keratosis

Intralesional recombinant IFN-á-2b has been shown to be effective in the treatment of squamous cell carcinoma (SCC) and actinic keratosis (AK). When IFN-á-2b was administered at a dose of 1.5 million IU three times/ week for 3 weeks to SCC lesions, 33 of 34 (97.1%) lesions showed an absence of SCC histologically.⁸ However, when compared to other treatments for AK, the use of IFN is limited by the pain of injections and the multiple follow-up visits necessary.

Cutaneous T-cell Lymphoma

IFN-a is one of the most effective single-therapy agents for the treatment of CTCL.⁹ Low-grade, nonHodgkin, T-cell lymphomas are always associated with cutaneous involvement and include mycosis fungoides (MF) and the Sézary syndrome (SS).¹⁰ A literature review by Bunn, et al. of 207 MF and SS cases treated with IFN- a-2a revealed an overall response rate of 55%, with 17% of cases being complete responders to IFN-a-2a therapy. These authors concluded that recombinant IFN-á-2a monotherapy has greater benefit in patients with early-stage disease, with 3 million IU of IFN-á-2a given subcutaneously three times/week being the optimal treatment regimen. In this study, no therapeutic differences were observed between IFN-á-2a and -2b.¹¹ A study by Vonderheid, et al. has revealed that intralesional injections of MF plaques with IFN-á-2b at a dose of 1 million IU given three times/week for 4 weeks produces substantial localized clinical and histological improvement with 10 of 12 plaques demonstrating complete regression localized to the IFN-á-2b injected sites.¹²

Kaposi’s Sarcoma

The use of IFN-a-2a and -2b in the treatment of KS in patients with acquired immune deficiency syndrome due to the human immunodeficiency virus has been approved by the US FDA. The recommended dosages for IFN-a-2a and -2b are 36 and 30 million IU subcutaneously three times/week, respectively. The average response rate of KS to high-dose IFN-á therapy has been approximately 30%. In many cases, tumor recurrence has been observed within 6 months after discontinuation of treatment, and response to subsequent treatments has not been reliable. This has led to indefinite treatment regimens until side-effects become intolerable.¹³

Imiquimod

As an immune response modifier, imiquimod induces IFN-á, tumor necrosis factor (TNF)-a, IL-1, IL-6, IL-8, and IL-12 production by monocytes, macrophages and toll-like receptor (TLR)-7-bearing plasmacytoid dendritic cells. TLR-7 is an essential receptor for imiquimodinduced immune responses.¹⁴ Imiquimod also generates production of IFN-a after CD4 cells are stimulated by IL-12. IFN-a stimulates cytotoxic T lymphocytes responsible for killing virus-infected and tumor cells.

Topical imiquimod 5% cream has been found to be effective in the treatment of lentigo maligna (LM, in situ melanoma). In a pilot, open-label, nonrandomized study evaluating the effectiveness of imiquimod 5% cream once daily for a maximum of 13 weeks on five patients with LM, a 100% response rate was observed without reoccurrence during a 3–18 month follow-up interval.¹⁵ Case reports describing multiple metastatic melanoma skin lesions clearing after topical imiquimod 5% cream application have also been published. The two patients studied applied imiquimod 5% cream three times/week to the metastatic skin lesions with a 1cm surrounding margin.¹⁶

Basal Cell Carcinoma

Imiquimod 5% cream has been shown to induce the expression of FasR on BCC cells, and FasR mediated apoptosis may contribute to the effectiveness of imiquimod in BCC treatment.¹⁷ An initial 16-week, dose-ranging, vehicle-controlled trial examining the effect of 5% imiquimod cream on nBCC and sBCC found an overall histological response rate of 83% (20/24) in the 5% imiquimod cream treatment group vs. 9% (1/11) in the vehicle treatment group.18 Subsequent sBCC randomized, multicenter studies have reported 100% efficacy with twice daily application vs. 73–88% efficacy with once daily application of 5% imiquimod cream.^19–21

Squamous Cell Carcinoma/ Actinic Keratosis

Imiquimod studies in SCC patients are restricted to AK and in situ SCC clinical presentations. A 16-week, twice weekly, imiquimod 5% cream treatment regimen has been approved by the FDA for patients with AK lesions on the face or scalp. This treatment regimen has achieved a 45.1% (97/215) complete clearance and a 59.1% (127/215) partial clearance rate. These clearance rates are significantly higher than the complete and partial clearance rates found in the vehicle group (p< 0.001).²²

Bowen’s Disease

Current therapies for Bowen’s disease, or intraepidermal SCC, include 5-Fluorouracil, surgical excision, curettage, electrocautery, cryo-, laser-, photo-, and radiotherapy.²³ In a Phase II open-label study, 16 biopsyproven plaques of Bowen’s disease, with diameters ranging between 1–5.4 cm, were treated once daily for 16 weeks with imiquimod 5% cream. Of the 16 lesions treated, 15 were on the lower extremities and 1 was on the shoulder. Fourteen of 15 patients (93%) had no residual tumor present in the 6-week post-treatment follow-up biopsy. Thirteen patients were followed to 6 months without disease recurrence.²⁴

Extramammary Paget’s Disease

Extramammary Paget’s disease (EMPD) is an infrequent epidermal malignancy most commonly occurring in the anogenital and vulvar regions. Therapeutic modalities
include wide local excision and Mohs micrographic surgery. A case report of two patients with primary limited cutaneous perineal and genital EMPD describes successful treatment of EMPD with imiquimod 5% cream, with confirmation of cure after 7.5–12 weeks of monotherapy. The treatment-associated morbidity was minimal when compared with other more invasive therapies.²⁵ Another case study has documented the eradication of EMPD of the scrotum in a 68-year-old male with nightly application of imiquimod 5% cream for 6 weeks, with no signs of reoccurrence at 6 months after discontinuation of therapy.²⁶

VIN

Imiquimod was preconceived as possibly beneficial in the treatment of VIN of human papilloma virus etiology, due to its antiviral and antineoplastic properties; however, the literature shows mixed results. In a prospective, observational study examining the effects of imiquimod 5% cream three times/week for 16 weeks in 15 patients with high-grade VIN, 3 demonstrated local side-effects, including soreness, burning, erythema, ulceration, and blistering. One patient required hospitalization, catheterization, and analgesia. Of the 13 patients who completed the study, four demonstrated clinical improvement. Of these four patients, only one had a negative VIN biopsy. All four patients who responded clinically relapsed 4 months after treatment.²⁷However, in a recent study examining the effect of imiquimod 5% cream applied three times/week for a maximum of 16 weeks in eight patients with biopsy-proven bowenoid and basaloid, VIN 2/3 had better results. Total clearance and partial clearance was observed in six patients and two patients, respectively, and the post-treatment biopsy showed an absence of precancerous lesions in seven of eight patients (87.5%).²⁸

Dendritic Cell-based Therapy

The use of autologous dendritic cells (DCs) loaded with tumor-associated antigens as a natural adjuvant to actively prime an effective immune response against tumor cells is also being investigated.^29–35 A Phase I clinical trial by Escobar, et al. designed to address the safety and efficacy of immunizations with tumor lysateloaded DCs in Stage III–IV metastatic melanoma patients found a significantly longer post-vaccination survival in patients with a delayed type IV hypersensitivity reaction against the melanoma cell lysate (17.25 months) than in nonresponders (8.625 months), (p=0.0261).³⁶ This study demonstrated that the vaccination procedure used was safe and could induce a clinical and immunologic response in patients with advanced melanoma, like other studies with comparable protocols.^35,37 However, a recent randomized Phase III clinical trial studying the effect of dacarbazine monochemotherapy vs. vaccination with autologous peptide-pulsed DCs in patients with metastatic melanoma found Grade 3/4 toxicities in seven patients in each treatment arm, and a total of 75 deaths at median follow up of 22.2 months. No significant differences were found in overall or progression-free survival between the two treatment arms.²⁹

Interleukin-2

Cutaneous Melanoma

Dose-related serious toxicities have limited IL-2 studies in melanoma patients, and low-dose IL-2 therapy has produced disappointing clinical response rates.³⁸ When high-dose, 100,000 units/kg, intravenous, recombinant IL-2 was examined in 47 patients with metastatic malignant melanoma, up to 20% achieved objective responses; however, three patients developed myocardial infarction and one patient died during therapy.³⁹ IL- 2-based biochemotherapy (IL-2, IFN-á-2b, cisplatin, dacarbazine, and vinblastine) has shown a response rate of 48%. It appears that this combination is statistically superior to either IL-2 or chemotherapy alone.⁴⁰ Results of ongoing trials may clarify the true value of IL-2 incombination chemotherapy.

IL-12

Cutaneous T-cell Lymphoma

CTCL presents with marked defects in IL-12 production, and progression of CTCL has been associated with profound defects in cell-mediated immunity and cytokine production. A Phase I dose-escalation trial examined the effect of recombinant human IL-12 (rhIL- 12) at a concentration of 50ng/kg, 100ng/kg, or 300ng/ kg, given two times/week subcutaneously for up to 24 weeks in 10 patients with CTCL. A complete clinical response (CR) was defined as complete disappearance of all measurable CTCL lesions for at least 1 month. A partial response (PR) was defined as at least 50% disappearance of all CTCL skin lesions for at least 1 month. Only patients with plaque stage disease (n=2) presented a CR. Two plaque stage patients and one Sézary syndrome patient had a PR. None of the T3 stage patients responded to the rhIL-12 treatment. The authors announced the development of future Phase II/III clinical trials based on the high response rate of plaque stage CTCL patients to rhIL-12.⁴¹

Future clinical trials on immunomodulators will continue to change the approach, management, and follow-up of skin cancer patients. These skin cancer therapies will continue to be based on principles governing the immune system. As our knowledge of the immune system continues to grow, the application of safe and efficacious immunomodulators to treat skin cancer will continue to change the practice of dermatology.

References

1. Creagan ET, Dalton RJ, Ahmann DL, et al. Randomized, surgical adjuvant clinical trial of
   recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol 13(11):2776- 83 (1995 Nov).
2. Rusciani L, Petraglia S, Alotto M, Calvieri S, Vezzoni G. Postsurgical adjuvant therapy for melanoma. Evaluation of a 3-year randomized trial with recombinant interferon-alpha after 3 and 5 years of follow-up. Cancer 79(12):2354-60 (1997 Jun).
3. Fluck M, Kamanabrou D, Lippold A, Reitz M, Atzpodien J. Dose-dependent treatment benefit in high-risk melanoma patients receiving adjuvant highdose interferon alfa-2b. Cancer Biother Radiopharm 20(3):280-9 (2005 Jun).
4. Buechner SA, Wernli M, Harr T, Hahn S, Itin P, Erb P. Regression of basal cell carcinoma by
   intralesional interferon-alpha treatment is mediated by CD95 (Apo-1/Fas)-CD95 ligand induced suicide. J Clin Invest 100(11):2691-6 (1997 Dec).
5. Buechner SA. Intralesional interferon alfa- 2b in the treatment of basal cell carcinoma. Immunohistochemical study on cellular immune reaction leading to tumor regression. J Am Acad Dermatol 24(5 Pt 1):731-4. (1991 May).
6. Greenway HT, Cornell RC, Tanner DJ, Peets E, Bordin GM, Nagi C. Treatment of basal cell carcinoma with intralesional interferon. J Am Acad Dermatol 15(3):437-43 (1986 Sep).
7. Stenquist B, Wennberg AM, Gisslen H, Larko O. Treatment of aggressive basal cell carcinoma with intralesional interferon: evaluation of efficacy by Mohs surgery. J Am Acad Dermatol 27(1):65-9. (1992 July).
8. Edwards L, Berman B, Rapini RP, et al. Treatment of cutaneous squamous cell carcinomas by intralesional interferon alfa-2b therapy. Arch Dermatol 128(11):1486-9 (1992 Nov).
9. Apisarnthanarax N, Duvic M. Cutaneous T-cell lymphoma. New immunomodulators. Dermatol Clin 19(4):737-48 (2001 Oct).
10. Broder S, Bunn PA Jr. Cutaneous T-cell lymphomas. Semin Oncol 7(3):310-31 (1980 Sep).
11. Bunn PA Jr, Hoffman SJ, Norris D, Golitz LE, Aeling JL. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sézary syndrome). Ann Intern Med 121(8):592-602 (1994 Oct).
12. Vonderheid EC, Thompson R, Smiles KA, Lattanand A. Recombinant interferon alfa-2b in plaque-phase mycosis fungoides. Intralesional and low-dose intramuscular therapy. Arch Dermatol 123(6):757-63 (1987 Jun).
13. Krown SE. Interferon and other biologic agents for the treatment of Kaposi’s sarcoma. Hematol Oncol Clin North Am 5(2):311-22 (1991 Apr).
14. Stockfleth E, Trefzer U, Garcia-Bartels C, Wegner T, Schmook T, Sterry W. The use of toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview. Br J Dermatol 149 Suppl 66:53-6 (2003 Nov).
15. Wolf IH, Cerroni L, Kodama K, Kerl H. Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod. Arch Dermatol 141(4):510-4 (2005 Apr).
16. Wolf IH, Cerroni L, Kodama K, Kerl H. Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod. Arch Dermatol 141(4):510-4 (2005 Apr).
17. Berman B, Sullivan T, De Araujo T, Nadji M. Expression of Fas-receptor on basal cell carcinomas after treatment with imiquimod 5% cream or vehicle. Br J Dermatol 149 Suppl 66:59-61 (2003 Nov).
18. Beutner KR, Geisse JK, Helman D, Fox TL, Ginkel A, Owens ML. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 41(6):1002-7 (1999 Dec).
19. Marks R, Gebauer K, Shumack S, et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week doseresponse trial. J Am Acad Dermatol 44(5):807-13 (2001 May).
20. Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two Phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 50(5):722-33 (2004 May).
21. Schulze HJ, Cribier B, Requena L, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehiclecontrolled Phase III study in Europe. Br J Dermatol 152(5):939-47 (2005 May).
22. Lebwohl M, Dinehart S, Whiting D, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two Phase III, randomized, doubleblind, parallel group, vehicle-controlled trials. J Am Acad Dermatol 50(5):714-21 (2004 May).
23. Cox NH, Eedy DJ, Morton CA. Guidelines for management of Bowen’s disease. British Association of Dermatologists. Br J Dermatol 141(4):633-41 (1999 Oct).
24. Mackenzie-Wood A, Kossard S, de Launey J, Wilkinson B, Owens ML. Imiquimod 5% cream in the treatment of Bowen’s disease. J Am Acad Dermatol 44(3):462-70 (2001 Mar).
25. Zampogna JC, Flowers FP, Roth WI, Hassenein AM. Treatment of primary limited cutaneous Skin Therapy Letter • Editor: Dr. Stuart Maddin • Vol. 11 No. 5 • June 2006 7 extramammary Paget’s disease with topical imiquimod monotherapy: two case reports. J Am Acad Dermatol 47(4 Suppl):S229-35 (2002 Oct).
26. Berman B, Spencer J, Villa A, Poochareon V, Elgart G. Successful treatment of extramammary Paget’s disease of the scrotum with imiquimod 5% cream. Clin Exp Dermatol 28 Suppl 1:36-8 (2003 Nov).
27. Todd RW, Etherington IJ, Luesley DM. The effects of 5% imiquimod cream on high-grade vulval intraepithelial neoplasia. Gynecol Oncol 85(1):67-70 (2002 Apr).
28. Marchitelli C, Secco G, Perrotta M, Lugones L, Pesce R, Testa R. Treatment of bowenoid and basaloid vulvar intraepithelial neoplasia 2/3 with imiquimod 5% cream. J Reprod Med 49(11):876-82 (2004 Nov).
29. Schadendorf D, Ugurel S, Schuler-Thurner B, et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized Phase III trial of the DC study group of the DeCOG. Ann Oncol 17(4):563-70 (2006 Apr).
30. Di Nicola M, Carlo-Stella C, Mortarini R, et al. Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma. Clin Cancer Res 10(16):5381-90 (2004 Aug).
31. Lau R, Wang F, Jeffery G, et al. Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma. J Immunother 24(1):66- 78 (2001 Jan-Feb).
32. Schuler-Thurner B, Dieckmann D, Keikavoussi P, et al. Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocytederived dendritic cells. J Immunol 165(6):3492-6 (2000 Sep).
33. Thurner B, Haendle I, Roder C, et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190(11):1669-78 (1999 Dec).
34. Baar J. Clinical applications of dendritic cell cancer vaccines. Oncologist 4(2):140-4 (1999).
35. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4(3):328-32 (1998 Mar).
36. Escobar A, Lopez M, Serrano A, et al. Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients. Clin Exp Immunol 142(3):555- 68 (2005 Dec).
37. Banchereau J, Palucka AK, Dhodapkar M, et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 61(17):6451-8 (2001 Sep).
38. Atkins MB. Interleukin-2: clinical applications. Semin Oncol 29(3 Suppl 7):12-7 (2002 Jun).
39. Parkinson DR, Abrams JS, Wiernik PH, et al. Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study. J Clin Oncol 8(10):1650-6 (1990 Oct).
40. McDermott DF, Mier JW, Lawrence DP, et al. A Phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma. Clin Cancer Res 6(6):2201-8 (2000 Jun).
41. Rook AH, Wood GS, Yoo EK, et al. Interleukin- 12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 94(3):902-8 (1999 Aug).
42. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14(1):7-17 (1996 Jan).
43. Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/ S9111/C9190. J Clin Oncol 18(12):2444-58 (2000 Jun).
44. Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 19(9):2370-80 (2001 May).
45. Korman N, Moy R, Ling M, et al. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two Phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials. Arch Dermatol 141(4):467-73 (2005 Apr).